The Entopsis team is excited to welcome Randy Rusz as Vice President of Business Development for North America. This addition will provide the research and clinical testing communities better access to our R&D team’s innovative solutions aimed at solving key industry problems.

Randy brings over 25 years of experience commercializing numerous life science technologies. He has direct experience with diagnostics, unique medical devices, infectious diseases / oncology, reagents / kits, instrumentation, and many more key areas that perfectly complement Entopsis’ technology pipeline. Randy uniquely combines deep insights from large life sciences companies (e.g., Roche, Lab Corp,

PCRopsis™ Reagent RVD was recently shown to mediate direct PCR amplification from viral and bacterial targets using low volumes of reagent and sample, thus drastically lowering costs and increasing testing accessibility.

Reagent RVD is a flexible direct PCR product for various research and clinical applications. The PCR testing industry is particularly price-conscious, with thin profit margins. As such, laboratories seek affordable and accurate solutions to offer clients the best services.

Recent miniaturization studies confirm Reagent RVD facilitates extraction-free RT-PCR and qPCR for less than $1.70 per reaction. Typically, RNA and DNA extraction kits cost $4.00 ~ $7.00 per extraction (2~4

Have you ever read about cool, new medical products / tests, only to later realize it won’t be available for years into the future (if ever)?

Entopsis is effectively a R&D company that creates novel, impactful technologies for the bio-medical space. They are best known for OpsisDx (single platform to diagnose diseases early through urine) and PCRopsis (clinical tools that make diagnostic tests more efficient). This team of hard-core scientists and engineers usually rather license technologies, than sell directly to consumers.

This is where the Global Health Institute (GHI) comes in. GHI’s mission is to de-risk new clinical technologies by

Reagent RVD has proven capable of amplifying SARS-CoV-2 gene targets directly from universal viral transport (UVT) medium without the need for viral RNA extraction. However, diagnostic reference laboratories also want to use this approach for the amplification of bacterial gene targets.

The PCRopsis research team has extended their validation efforts in this direction. It’s been confirmed that Reagent RVD is capable of mediating extraction-free qPCR of specimens containing gram positive and negative bacteria.

To date, Reagent RVD facilitates extraction-free amplification of viral, bacterial and human gene targets directly from UVT.

This opens the door to new applications with Reagent

Genetics Institute of America (GIA) received IRB approval to expand its Prostate Cancer Study (GH215) utilizing OpsisDx to include: Breast, Ovarian and Lung Cancers. OpsisDx will be used to develop accurate, non-invasive tests for the early detection of these 3 additional cancers.

GIA, empowered by OpsisDx, will be able to screen people for prostate, breast, ovarian, and / or lung cancers once these 4 studies are completed. These tests are expected to detect tumors earlier than liquid biopsies and thereby outperform GRAIL (valued at over $4 billion).

The Entopsis team will continue to support GIA’s efforts of bring impactful tools

Is viral RNA extraction necessary for amplifying genes from coronaviruses, like SARS-CoV-2?

NOT ANY MORE!

PCRopsis Reagent RVD allows you to perform direct RT-qPCR from nasopharyngeal / oropharyngeal samples transported in BD Universal Viral Transport media or Copan ESwab.

Simple Protocol:

  1. Mix sample 1:1 with Reagent RVD
  2. Heat to 95C for 10 minutes
  3. DONE… use ~5 uL into your RT-qPCR mix (can use 5 uL into a total 20 uL reaction)

Key Features:

  • Reagent RVD is an alternative to RNA extraction
  • Offers comparable RT-qPCR results to RNA extraction procedures for many applications in 10 MINUTES
  • Cost a fraction of traditional RNA extraction procedures, with fewer steps
  • Compatible with leading

Our team submitted a research manuscript for peer-review describing the unique approach utilized by OpsisDx to categorize samples and patients. We included data from a clinical study as a means of validating the platform for clinical use.

Entopsis recently signed licensing agreements with a CLIA-certified diagnostic laboratory to commercialize 4 oncology OpsisDx tests in the USA. This represents the first step in bringing OpsisDx to market.

The Entopsis team continues to prove-out the capabilities of OpsisDx for the early detection of other cancers, infectious diseases and mental illnesses. These efforts are aimed at establishing additional partnerships globally for a variety of medical conditions so that we can offer better health outcomes to all people.

Digital photo of Venetian highway, Miami modified from photo taken by Marc Averette (CC BY-SA 3.0).

This is just hot off the press. The Greater Miami Chamber of Commerce yesterday awarded Entopsis the Most Disruptive Technology Award. The Chamber has had an illustrious history dating back to 1907 when it was chartered to take over the functions of the Miami Board of Trade and Merchants’ Association. Since inception, the Chamber has played an active role in shaping events and commercial development in Miami. Entopsis is honored to be recognized by the Chamber for being a leading innovator in Miami. Our intrepid CEO, Dr.